Skip to main content
Premium Trial:

Request an Annual Quote

NIH to Fund Collaborations with National Centers for Biomedical Computing

NEW YORK, March 8 (GenomeWeb News) - The National Institutes of Health last week issued a funding program entitled "Collaborations with National Centers for Biomedical Computing."

 

The program, using the R01 funding mechanism, intends to fund projects from individual investigators or small groups to collaborate with the recently-formed National Centers for Biomedical Computing. The intention is to engage researchers across the USin building an excellent biomedical computing environment, using the computational tools and biological and behavioral application drivers of the funded NCBCs as foundation stones, according to the NIH.

 

The size and duration of each award will vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

 

The first round of applications are due May 17.

 

Additional information is available here.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.